S, V., P, S., & CN, Y. (2024). Ertapenem Versus Meropenem for the Treatment of Extended Spectrum Beta-Lactamase-Producing Enterobacterales Bacteremia in Critically Ill Patients. The Annals of pharmacotherapy, 58(7), 690. https://doi.org/10.1177/10600280231205219
Chicago Style (17th ed.) CitationS, VanDorf, Shah P, and Yost CN. "Ertapenem Versus Meropenem for the Treatment of Extended Spectrum Beta-Lactamase-Producing Enterobacterales Bacteremia in Critically Ill Patients." The Annals of Pharmacotherapy 58, no. 7 (2024): 690. https://doi.org/10.1177/10600280231205219.
MLA (9th ed.) CitationS, VanDorf, et al. "Ertapenem Versus Meropenem for the Treatment of Extended Spectrum Beta-Lactamase-Producing Enterobacterales Bacteremia in Critically Ill Patients." The Annals of Pharmacotherapy, vol. 58, no. 7, 2024, p. 690, https://doi.org/10.1177/10600280231205219.